Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [2] - The company has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [2] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [2] Upcoming Events - Michael Raab, President and CEO, and Justin Renz, Chief Financial and Operations Officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on June 5, 2024, at 10:00 A.M. Eastern Time in New York City [1] - A live webcast of the panel presentation will be available on the Ardelyx website, with a replay accessible for 30 days following the event [1]